Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Atazanavir Sulfate

Client Email

Product

Atazanavir Sulfate
CAS 1292296-09-3
CAS 162537-11-3
US Patents

Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Atazanavir Sulfate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

42 API Suppliers, 25 USDMF, 6 CEP/COS, 15 EU WC, 2 KDMF, 18 NDC API, 21 Listed Suppliers, $ API Reference Price

42 API Suppliers
25 USDMF
6 CEP/COS
15 EU WC
2 KDMF
18 NDC API
21 Listed Suppliers
$ API Reference Price

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

FINISHED DOSAGE FORMULATIONS

69 FDF Dossiers, 42 FDA Orange Book, 8 Europe, 11 Canada, 2 South Africa, 6 Listed Dossiers

69 FDF Dossiers
42 FDA Orange Book
8 Europe
11 Canada
2 South Africa
6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

TABLET;ORAL - EQ 300MG BASE;150MG
CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 200MG BASE
CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 8 DKSH, 1 Jai Radhe Sales, 10 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 17 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 1 Valens Pharmachem, 4 Vasa Pharmachem

1 Rochem International Inc
1 SPI Pharma
8 DKSH
1 Jai Radhe Sales
10 Gangwal Healthcare
3 Nanjing Well Pharmaceutical
1 Pfanstiehl
4 ACG Worldwide
1 Actylis
6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
8 BASF
6 DFE Pharma
1 Finar
6 Gangwal Chemicals
1 Ideal Cures Pvt Ltd
2 Ingredion Pharma Solutions
17 Kerry
3 Lonza Capsugel
12 Microlex e.U
2 Pharmatrans-Sanaq
4 Pluviaendo
4 Prachin Chemical
1 Qualicaps
14 Roquette
3 Seppic
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
11 Sigachi Industries
1 Valens Pharmachem
4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

47 Fillers, Diluents & Binders, 23 Disintegrants & Superdisintegrants, 22 Direct Compression, 21 Thickeners and Stabilizers, 17 Lubricants & Glidants, 15 Granulation, 13 Coating Systems & Additives, 11 Co-Processed Excipients, 8 Film Formers & Plasticizers, 8 Empty Capsules, 7 Taste Masking, 7 Topical, 7 Emulsifying Agents, 5 Controlled & Modified Release, 4 Solubilizers, 4 Parenteral, 3 Surfactant & Foaming Agents, 3 Coloring Agents, 3 Chewable & Orodispersible Aids, 2 Rheology Modifiers, 1 API Stability Enhancers

47 Fillers, Diluents & Binders
23 Disintegrants & Superdisintegrants
22 Direct Compression
21 Thickeners and Stabilizers
17 Lubricants & Glidants
15 Granulation
13 Coating Systems & Additives
11 Co-Processed Excipients
8 Film Formers & Plasticizers
8 Empty Capsules
7 Taste Masking
7 Topical
7 Emulsifying Agents
5 Controlled & Modified Release
4 Solubilizers
4 Parenteral
3 Surfactant & Foaming Agents
3 Coloring Agents
3 Chewable & Orodispersible Aids
2 Rheology Modifiers
1 API Stability Enhancers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 10 NEWS #PharmaBuzz

2 DATA COMPILATION #PharmaFlow
10 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 5 Annual Reports

2 US Medicaid Prescriptions
5 Annual Reports

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 8 Health Canada Patents

2 US Patents
8 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 1 Others

2 USP
1 Others

$ API Ref.Price (USD/KG) : 879 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

2 All

01 2BRISTOL

filter Patent Number Reset all filters

2 All

01 18148374

02 110039718

filter API Patent Reset all filters

2 All

01 1Y

02 1Blank

filter FDF Patent Reset all filters

2 All

01 2Y

filter Expiration Date Reset all filters

2 All

01 12029-09-03

02 12032-10-06

US Patents
Health Canada Patents

Product Main Page

01

BRISTOL

ATAZANAVIR SULFATE; COBICISTAT

AAPS 2024

Not Confirmed

BRISTOL

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-03

ATAZANAVIR SULFATE; COBICISTAT

US Patent Number : 8148374

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206353

Patent Use Code : U-1279

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2029-09-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

BRISTOL

ATAZANAVIR SULFATE; COBICISTAT

AAPS 2024

Not Confirmed

BRISTOL

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-10-06

ATAZANAVIR SULFATE; COBICISTAT

US Patent Number : 10039718

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206353

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?